The addition of FES-PET to NCCN guidelines is more than a clinical endorsement; it's a critical lever for overcoming access barriers. This inclusion signals to insurance payers that the imaging should be covered and prompts unfamiliar oncologists to learn about and adopt the technology, accelerating its transition into standard care.

NCCN guidelines for folate receptor alpha and HER2 in ovarian cancer allow treatment at lower expression levels than initial trials. This is driven not only by data showing activity in these groups but also by the fact that the original smaller biotech developers had limited resources for expansive trials beyond the highest-expressing cohorts, a commercial factor influencing current clinical guidance.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

The RECITE trial proved romiplostim effectively maintains platelet counts, allowing patients to receive their full, intended chemotherapy dose (relative dose intensity). However, the critical link between maintaining this dose and actually improving progression-free or overall survival has not yet been established.

In the absence of direct evidence for adjuvant therapy in high-risk, non-clear cell kidney cancers, clinicians may justify off-label treatment by extrapolating from the drug's known efficacy in the metastatic setting for that specific histology. This highlights the difficult risk-benefit calculations made daily in data-poor clinical scenarios.

While pirtobrutinib was already used off-label per NCCN guidelines, its official FDA approval provides a government-sanctioned alternative, forcing a direct decision between it and a venetoclax-based regimen for patients relapsing on a prior BTK inhibitor.

Unlike most cancers, National Comprehensive Cancer Network (NCCN) guidelines recommend clinical trials as the preferred first-line treatment for glioblastoma patients with good performance status. This rare recommendation highlights the dismal outcomes with existing therapies and the urgent need for therapeutic innovation.

Clinicians are pragmatically using novel drug combinations based on safety and early efficacy data from Phase 1b/2 trials like ELEVATE. This practice circumvents the impossibility of running Phase 3 trials for every permutation and is reportedly being covered by insurers, accelerating patient access to new options.

The drug is so effective and now NCCN-endorsed for chemotherapy-induced thrombocytopenia that recruiting patients for a placebo-controlled trial to prove long-term survival benefits is nearly impossible. Patients would refuse the risk of receiving a placebo when an effective treatment is available off-study.